roche

Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk

pharmafile | October 16, 2018 | News story | Manufacturing and Production, Sales and Marketing |  Cancer, Kadcyla, Roche, breast cancer, pharma 

Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early breast cancer (eBC) who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following pre-surgery treatment.

The results from the Phase 3 KATHERINE study indicated that Kadcyla met its primary endpoint, “significantly reducing” the risk of disease recurrence or death compared to Herceptin (trastuzumab) when used as an adjuvant therapy.

“We are highly encouraged by these positive results with adjuvant Kadcyla treatment in people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to discussions with regulatory authorities with the goal of bringing this new treatment option to patients as soon as possible.”

Full results from the study are due to be presented at the 2018 San Antonio Breast Cancer Symposium in December, and will be presented to global health authorities in the pursuit of marketing authorisation.

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

The Gateway to Local Adoption Series

Latest content